The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.
 
Miguel Martin
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Novartis (Inst); Roche (Inst)
 
Christoph Zielinski
Consulting or Advisory Role - Amgen; ARIAD; AstraZeneca; Athenex; Bristol-Myers Squibb; Fibrogen (Inst); Gilead Sciences; Imugene; Lilly; Merck KGaA; Merck Sharp & Dohme; Merrimack; Novartis; Pfizer; Roche; SERVIER; Shire (Inst); Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Manuel Ruiz-Borrego
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Speakers' Bureau - Lilly; Novartis; Pfizer
 
Eva Maria Carrasco
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Abbvie (I); Amgen (I); Bristol-Myers Squibb (I); Celgene (I); Incyte (I); Janssen (I); Novartis (I); Pfizer (I); Roche Pharma AG (I)
Research Funding - Abbvie (I); Amgen (I); AstraZeneca (Inst); AstraZeneca Spain (Inst); Bristol-Myers Squibb (I); Bristol-Myers Squibb (Inst); Celgene (I); Celgene (Inst); Janssen (I); Merck Sharp & Dohme (Inst); Novartis (I); Novartis (Inst); Pfizer (I); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (I); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - PAM 50 taxane predictor
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Celgene (I); Novartis (I); Roche
 
Eva Ciruelos
No Relationships to Disclose
 
Montserrat Muñoz
No Relationships to Disclose
 
Begoña Bermejo
Consulting or Advisory Role - Genentech/Roche; Novartis
 
Mireia Margeli Vila
No Relationships to Disclose
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)
 
Maribel Casas
No Relationships to Disclose
 
Antonio Anton
Consulting or Advisory Role - Bayer
 
Laura Murillo Jaso
No Relationships to Disclose
 
Istvan Lang
No Relationships to Disclose
 
Cynthia Huang Bartlett
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Maria Koehler
Employment - Bicycle Therapeutics; Repare Therapeutics
Stock and Other Ownership Interests - Agios; Amgen; Gilead Sciences; Merck; Pfizer
Honoraria - Atheneum; Gerson Lehrman Group
Consulting or Advisory Role - ERVAXX; Lilly Asia Ventures
 
Nuria Martin
No Relationships to Disclose
 
Massimo Corsaro
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Claire Swift
No Relationships to Disclose
 
Bella Nisenbaum
No Relationships to Disclose
 
Miguel J. Gil Gil
Honoraria - Eisai; Novartis; Pfizer
Consulting or Advisory Role - Agendia; Daiichi Sankyo; Genomic Health
Travel, Accommodations, Expenses - Daiichi Sankyo; Kern Pharma; Pfizer; Roche